Abstract
Abstract
The clinical evaluation of a meningococcal polysaccharide vaccine containing groups A, C, Y, and W135 antigens was described. The vaccine was found to be clinically acceptable and a significant antibody response was detected by both a bactericidal assay and a solid-phase radioimmune assay.
Get full access to this article
View all access options for this article.